What SUDx-Biotec does

SUDx-Biotec Corporation (株式会社スディックスバイオテック), founded in 2006 and headquartered at the Kagoshima University Venture Business Laboratory in Japan, is a private university-spinout diagnostic biotechnology company commercializing sugar chain nanotechnology. Its proprietary platform centers on Sugar Chain-Immobilized Gold Nano-Particles (SGNP, ~10 nm) and magnetic variants (mSGNP) that exploit the biology of virus-cell sugar chain interaction to capture, concentrate (~1,000-fold) and purify viruses from clinical saliva samples in roughly three minutes, enabling downstream RT-PCR detection at sensitivities down to 10 copies/μL. Founder and CEO Yasuo Suda, a Doctor of Engineering from Osaka University and Specially Appointed Professor at Kagoshima University, leads the company alongside a small team (11–50 employees) and an institutional venture shareholder base that includes QB Capital, Realtech Fund (UntroD Capital), and Miyazaki Taiyo Capital (combined ~¥350M raised through November 2020).

The company operates two productized business lines. The diagnostic line includes the PMDA-approved, insurance-listed SGNP nCoV PCR Detection Kit and SGNP nCoV/Flu combined kit (Japan national health insurance, 700 points/test), the SUDx oral microorganism PCR detection kits (3- and 6-species versions) for dental periodontal assessment via oral rinse, the SUDx PET Oral Microorganism PCR Detection Kit and Petoral Check for canine/feline periodontal screening, and an oral cancer risk screening kit launched in 2024. The research tools and services line sells SGNP reagent kits (13 sugar variants), Sugar Chip SPR/QCM sensor chips, custom GAG oligosaccharide synthesis (currently heparan sulfate; chondroitin, dermatan and keratan sulfate in preparation), and SPR imaging contract analysis services to academic and pharmaceutical customers globally.

The business model is anchored in B2B direct sales of regulated medical devices and dental diagnostics to Japanese institutions via the company website and inside sales ([email protected], [email protected]), complemented by an Amazon Japan direct-to-consumer channel for Petoral Check and a fee-for-service contract research arm. Reported clinical advantages — non-invasive saliva sampling, ~1,000-fold virus pre-concentration, simultaneous multi-pathogen detection, and quantitative bacterial load reporting with next-day turnaround — have supported adoption across internal medicine (e.g., Onishi Internal Medicine, ~130 patients tested), dental specialty clinics, veterinary dentistry (Park Animal Hospital / Aichi Animal Dental), and pharmaceutical research customers.

Name

SUDx-Biotec

Legal name

株式会社スディックスバイオテック

Website

https://sudxbiotec.jp

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

SUDx-Biotec develops sugar chain-immobilized gold nanoparticle (SGNP) PCR diagnostic kits for saliva-based infectious disease, dental periodontal, and pet oral health testing, plus SGNP reagents, Sugar Chip SPR sensors, and GAG oligosaccharide synthesis services for research and pharmaceutical customers.

Ownership category

akta.pro rank

Product category

Molecular diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Sugar chain nanotechnology
• PCR diagnostic kits
• Molecular diagnostics
• Saliva-based testing
• Glycan research reagents

Headquarters

HQ city

Kagoshima

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Test Kits Sales: Sale of PCR detection kits for medical use (SGNP nCoV/Flu PCR Detection Kit, SGNP nCoV PCR Detection Kit) to healthcare institutions, covered by national health insurance in Japan. Also pet oral microbiome PCR detection kits (SUDx PET Oral Microorganism PCR Detection Kit, Petoral Check) sold via Amazon and direct inquiry to veterinary clinics.
2. Sugar Chip and SGNP Research Reagent Sales: Sale of SGNP reagent kits (SGNPs #1 and #2 sets) and Sugar Chip products to academic and pharmaceutical research institutions for protein-sugar interaction analysis.
3. Sugar Chip Contract Analysis Services: Fee-for-service contract analysis using Sugar Chip SPR imaging and affinity kinetics measurement. Customers submit protein/virus samples; SUDx performs binding assays and delivers a report.
4. GAG Oligosaccharide Synthesis Services: Custom synthesis of homogeneous GAG (glycosaminoglycan) oligosaccharides (currently heparan sulfate) for research institutions and pharmaceutical companies, under NDA and project-based contract.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

SUDx-Biotec develops, manufactures, and commercializes diagnostic and research products built on its proprietary sugar chain nanotechnology (SGNP) platform. Its commercial offerings include PCR detection kits for SARS-CoV-2 and influenza A/B from saliva samples, oral microbiome PCR kits for dental and veterinary clinics (3-, 6-, and 9-pathogen configurations), the Petoral Check at-home pet oral screening kit, and research tools including SGNP reagent kits, Sugar Chip SPR/QCM sensor chips, and contract GAG oligosaccharide synthesis and binding analysis services.

Product overview

SUDx-Biotec Corporation is a diagnostic biotechnology company specializing in sugar chain nanotechnology (糖鎖ナノテクノロジー). The company operates two main business segments: (1) Diagnostic Products for human and veterinary use, including the SGNP nCoV/Flu PCR Detection Kit (COVID-19 and influenza A/B simultaneous detection), SUDx Oral Microorganism PCR Detection Kits for periodontal disease (3-type and 6-type Plus versions), Petoral Check home screening kit for pets, and oral cancer risk screening kit (in development); and (2) Research Tools & Services, including Sugar Chain Synthesis Services for GAG oligosaccharides, Sugar Chip sensor chips for SPR/QCM analysis, SGNP (sugar chain-immobilized gold nanoparticle) reagents and kits in 13 variants, and contract analysis services. The core SGNP technology enables rapid virus concentration (3 minutes with magnetic SGNP) and high-sensitivity detection from saliva specimens with results in 20-30 minutes for COVID-19.

Differentiator

Problem solved

Functional benefit

Products and services

• SGNP nCoV/Flu PCR Detection Kit Real-time RT-PCR detection kit for simultaneous detection of influenza A/B viruses and SARS-CoV-2 from saliva specimens, using proprietary SGNP virus capture and concentration. Approved as an in-vitro diagnostic medical device in Japan (insurance listed, 700 points per test). For hospitals, clinics, and infectious disease testing laboratories.
• SGNP nCoV PCR Detection Kit Real-time RT-PCR detection kit for SARS-CoV-2 from saliva specimens using SGNP-based virus concentration and purification. Approved for insurance-covered use in Japan; offered to medical institutions through direct sales.
• SARS-CoV-2 Detection Reagent (新型コロナウイルス(SARS-CoV-2)検査用試薬) Research-use SARS-CoV-2 genomic RNA PCR detection reagent with high accuracy at 10 copies/μL sensitivity, 3-minute pre-treatment, and 55-minute RT-PCR amplification using SGNP concentration.
• MuSER gene analysis device Gene analysis device for nucleic acid detection using SUDx's proprietary technology, with dedicated sample chips and operation methodology. Marketed alongside SUDx diagnostic kits.
• SUDx Oral Microorganism PCR Detection Kit (3-type) PCR detection kit measuring 3 periodontal pathogens (Porphyromonas gingivalis, Tannerella forsythensis, Treponema denticola) from oral rinse samples. Sold directly to dental clinics and hospitals (trial: 10 tests for ¥25,000, results within one week).
• SUDx Oral Microorganism PCR Detection Kit Plus (6-type) Expanded PCR detection kit measuring 6 oral bacteria plus total bacterial load (P. gingivalis, T. forsythensis, T. denticola, F. nucleatum, P. intermedia, A. actinomycetemcomitans, S. mutans). For comprehensive periodontal assessment including caries risk, used in dental clinics and hospitals.
• SUDx Oral Microorganism PCR Detection Kit for PET Oral microorganism PCR detection kit for dogs and cats testing up to 9 oral bacterial species including Porphyromonas gulae, using simple cotton swab sampling. Used by veterinary clinics for periodontal disease screening and pre-operative plaque control evaluation.
• Petoral Check At-home periodontal disease screening kit for pets using cotton swab sampling at the gum line; detects 3 periodontal pathogens (Porphyromonas gulae, Treponema denticola, Porphyromonas gingivalis) with results delivered by mail. Sold via Amazon Japan (ASIN B0H1LY521W) to individual pet owners and veterinary clinics.
• Feline Coronavirus (FCoV) PCR Detection service PCR testing service for detection of feline coronavirus (FCoV). Offered as a veterinary diagnostic service for companion animal clinics and cat owners.
• Sugar Chip Gold surface chip with sugar chains immobilized via linker molecules, used as a sensor chip for Surface Plasmon Resonance (SPR) and Quartz Crystal Microbalance (QCM) instruments to measure protein–virus–sugar chain interactions in real time without labels. Sold to academic and pharmaceutical research institutions globally.
• SGNP (Sugar Chain-Immobilized Gold Nano-Particle) reagent Sugar chain-immobilized gold nanoparticles (~10 nm diameter) used as research reagents for sugar-chain-selective binding with lectins and other sugar-binding proteins, causing aggregation/precipitation visible to the naked eye (wine-red color, ~530 nm absorption). Sold to academic and pharmaceutical research institutions.
• SGNP Kit (SGNPs #1 and #2) SGNP reagent kit set: SGNPs#1 (Code G-AB1-250) contains 11 neutral-sugar SGNPs; SGNPs#2 (Code G-AB2-250) adds 2 sialic acid-containing SGNPs for 13 total variants. Used by research labs for sugar-binding specificity profiling.
• Sugar Chip Contract Analysis Service Fee-for-service SPR imaging and affinity analysis using Sugar Chip technology to measure the interaction between client-submitted proteins and multiple sugar chains; includes high-throughput SPR imaging arrays and kinetic analysis with a delivered report. For research institutions and pharmaceutical companies.
• GAG Oligosaccharide (Sugar Chain) Synthesis Service Custom synthesis of homogeneous GAG (glycosaminoglycan) oligosaccharides under NDA-based contracts — currently offering heparan sulfate with iduronic acid; chondroitin sulfate, dermatan sulfate, and keratan sulfate in preparation. For molecular-level structure-activity research at research institutions and pharmaceutical companies.

Quantifiable outcome

• Virus concentration of ~1,000-fold, enabling detection below standard PCR detection limits
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered minor and core.

• 国立新加坡大学 (National University of Singapore)minorStrategic or Co-development Partner · 1 March 2020SUDx-Biotec CEO Suda Yasuo co-authored a chapter in the Singapore National University-edited SARS-CoV-2 Methods and Protocols book (Method in Molecular Biology 2452, 2022), co-authored with hospital physicians and Kagoshima University researchers.
• 鹿児島大学 (Kagoshima University)coreStrategic or Co-development Partner · 9 February 2017SUDx-Biotec was granted the 'Kagoshima University Certified Venture' designation (鹿児島大学認定ベンチャー) in February 2017. The company was spun out from Kagoshima University research. Founder/CEO Suda Yasuo holds a joint appointment as Specially Appointed Professor at Kagoshima University. Multiple co-developed patents are jointly owned with the university.
• カルピス株式会社 (Calpis Co., Ltd.)coreStrategic or Co-development Partner · 1 July 2011Calpis collaborated with SUDx-Biotec and Kagoshima University Suda Laboratory to conduct a clinical study using SUDx's ultra-sensitive influenza virus detection technology (nanoparticle-based method) to monitor influenza virus in saliva of subjects consuming Lactobacillus acidophilus L-92 yogurt. Results were presented at the Japanese Society of Lactic Acid Bacteria in 2011.
• 加州大學圣地亚哥分校 (UCSD)minorStrategic or Co-development PartnerOngoing information exchange and collaborative relationship with University of California San Diego (UCSD), including joint research on vaccine adjuvants. CEO Suda regularly traveled to the US to exchange information with UCSD researchers.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Eiken Chemical Co., Ltd. Eiken Chemical is a Japanese IVD manufacturer selling PCR kits, rapid antigen tests, and clinical chemistry reagents through the same national health insurance channels SUDx uses. Both companies are Japan-anchored, mid-sized diagnostic kit developers serving medical institutions; product overlap and go-to-market similarity make this the most directly comparable peer.
• Tauns Laboratories, Inc. Tauns Laboratories is a Japanese IVD company focused on infectious disease and cancer diagnostic kits with similar sales patterns via direct-to-clinic and pharmacy channels. Comparable in scale and regulatory pathway as a Japan-based diagnostic kit specialist competing for the same clinical accounts.
• Cepheid (Danaher): Cepheid is a global leader in rapid molecular PCR diagnostics with its GeneXpert platform, including the Xpert Xpress SARS-CoV-2 and influenza co-detection tests. Directly comparable technology category (automated rapid PCR) and end-users (clinics running single-sample molecular testing), although vastly larger scale and US-led.
• Bako Diagnostics: Bako Diagnostics operates a dental PCR testing service that processes oral samples for periodontal pathogens and submits results to dentists. Directly comparable business model in the dental oral-microbiome vertical where SUDx markets its SUDx Oral Microorganism PCR Detection Kit, and targets the same dental practice customers.
• Mizuho Medy Co., Ltd. Mizuho Medy is a Japanese manufacturer of IVD reagents and pregnancy/fertility test kits. Comparable as a mid-sized Japanese IVD kit maker selling into the same medical institution and pharmacy channels under Japanese insurance and OTC frameworks, with similar scale and product development model.

Broad incumbents

• IDEXX Laboratories, Inc. IDEXX is the dominant companion-animal diagnostics provider globally, with extensive veterinary PCR and reference lab services including periodontal pathogen testing. Overlaps with SUDx's Petoral Check pet oral microbiome kit in the same end-customer segment (veterinary dental clinics) and disease category (companion-animal oral infection).
• Sysmex Corporation: Sysmex is a large Japanese diagnostics leader in hematology, urinalysis, and life science research, with growing activity in molecular diagnostics and reagents. Comparable as a Japan-headquartered IVD/life-science-tools company that dominates similar customer accounts, though at vastly larger scale and broader product portfolio.
• Hologic, Inc. Hologic is a global molecular diagnostics incumbent with the Panther system and Aptima assays for infectious disease including SARS-CoV-2 and influenza. Competes with SUDx in the high-sensitivity molecular infectious disease testing category served by hospital and reference laboratories, with vastly broader menu and distribution.

Emerging players

• T2 Biosystems, Inc. T2 Biosystems develops nanoparticle-based diagnostic platforms that detect pathogens directly from clinical samples without PCR amplification. Comparable technology paradigm (nanoparticle-driven capture and detection) and target market (rapid infectious disease diagnostics), though operating at earlier commercial stage and focused on sepsis and blood-cultured pathogens.
• Salimetrics, LLC: Salimetrics specializes in saliva-based diagnostic collection devices and assay services for hormones, stress, and infectious disease research. Comparable niche focus on saliva as the diagnostic sample matrix and similar emphasis on non-invasive sampling advantages, though primarily serves research and wellness rather than insurance-reimbursed clinical testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sudx-biotech-taiwan

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SUDx-Biotec